Didier Wimmers, Executive Vice President of Research and Development at Aehr Test Systems (NASDAQ: AEHR), sold a total of 5,400 shares of the company's common stock in two transactions on April 13 and April 15, 2026, a Form 4 filed with the Securities and Exchange Commission shows.
The combined proceeds from the two dispositions amounted to $385,731. Prices for the shares sold ranged from $71.1102 to $72.0239 per share.
In the first trade on April 13, Wimmers disposed of 3,500 shares at $71.1102 per share. After that transaction, he directly held 12,559 shares of Aehr Test Systems stock.
The second sale took place on April 15, when Wimmers sold 1,900 shares at $72.0239 per share. Following the April 15 sale, his direct holdings stood at 10,659 shares, a total that the filing notes includes unvested restricted stock units. Both transactions were executed with formal authorization signed by Chris Siu, Attorney-in-Fact.
Wimmers' sales come as AEHR shares trade near their 52-week high of $74.72, capping a roughly 771% advance over the past year. That price performance sits alongside a valuation assessment from InvestingPro indicating the stock appears overvalued at current market levels, with the firm's Fair Value notably below the market price. The InvestingPro reference notes that more detailed valuation metrics and additional analysis are available in its Pro Research Report.
Financial disclosures for Aehr Test Systems' third quarter of fiscal 2026 reflect mixed operating results. The company reported revenue of $10.3 million, a figure slightly below the consensus estimate of $10.8 million. On an earnings-per-share basis, Aehr posted -$0.05, outperforming the forecasted -$0.07.
Despite the modest revenue shortfall, Aehr reported record quarterly bookings of $37.2 million, producing a book-to-bill ratio in excess of 3.5 times and leaving the company with a backlog greater than $50 million. That bookings momentum has triggered analyst updates from market participants: Freedom Broker raised its price target to $61 while maintaining a Hold rating, and Lake Street lifted its price target to $56 and reiterated a Buy rating.
The Form 4 filing and the company financials together present a mix of signals: sizable insider selling at prices near recent highs, a valuation view that flags potential overvaluation, and operational metrics that include robust bookings and an improving backlog.
Investors evaluating AEHR can reference the SEC filing details for the insider transactions and the company's disclosed quarterly results for additional context on recent performance and demand indicators.